What does BIOMEDICAL SYSTEMS do?

BIOMEDICAL SYSTEMS is a research organisation in Leuven. Private Limited, started on 2 October 1981, 1 establishment.

What is the address of BIOMEDICAL SYSTEMS?

The registered office of BIOMEDICAL SYSTEMS is located at Diestsepoort 1, 3000 Leuven.

Is BIOMEDICAL SYSTEMS still active?

Yes. According to the CBE (29 October 2026) BIOMEDICAL SYSTEMS is active, legal situation “Normale toestand”, started on 2 October 1981.

Is BIOMEDICAL SYSTEMS registered on Peppol?

Yes, BIOMEDICAL SYSTEMS is registered on the Peppol network with ID 0208:0421984741.

What is the enterprise number of BIOMEDICAL SYSTEMS?

The enterprise number of BIOMEDICAL SYSTEMS is BE0421984741.

When was BIOMEDICAL SYSTEMS founded?

BIOMEDICAL SYSTEMS was founded on 2 October 1981.

Who are the directors of BIOMEDICAL SYSTEMS?

According to the 2025 annual accounts, the directors of BIOMEDICAL SYSTEMS are: Timothy COBB, Christopher FIKRY, Jason KNOBLAUCH.

Is BIOMEDICAL SYSTEMS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 October 1981; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did BIOMEDICAL SYSTEMS make in 2025?

BIOMEDICAL SYSTEMS posted a profit after taxes of € 594,055 in financial year 2025.

What is the revenue of BIOMEDICAL SYSTEMS?

As a small company, BIOMEDICAL SYSTEMS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 3,669,996.

How much does an employee at BIOMEDICAL SYSTEMS earn?

The average wage cost per full-time employee at BIOMEDICAL SYSTEMS was € 117,600 in 2025: staff costs of € 2.6 million for 22.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does BIOMEDICAL SYSTEMS have?

According to the 2025 annual accounts, BIOMEDICAL SYSTEMS has 22.3 full-time equivalents (FTE).

BIOMEDICAL SYSTEMS (Private Limited) - Leuven

Dossier BIOMEDICAL SYSTEMS, printed on 29 October 2026 from databakkes.be/en/0421984741/biomedical-systems. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 34.8 to 22.3.

Financials

Financial year 2025

BIOMEDICAL SYSTEMS from Leuven, company number BE0421984741, closed financial year 2025 with a result of € 594,055 after tax. For that financial year BIOMEDICAL SYSTEMS recorded a gross margin of € 3.7 million and equity of € 9.1 million. Compared with financial year 2024, the result moved from € 374,589 to € 594,055. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.

What it is worth Growing

€ 9.1 million

▲ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 594,055

▲ 59% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 467,803

▼ 49% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 9 million.

People and assets in 2025

Full-time equivalents

22.3

▼ 5.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 2.6 million

▼ 22% vs 2024

€ 117,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 236,813

▲ 64% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 716,427

▲ 66% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 4,685,440 Gross margin 2022: € 4,685,440 First fiscal year in the series	€ 4,959,402 Gross margin 2023: € 4,959,402 ▲ 6% vs 2022 (€ 4,685,440) Favourable step	€ 3,927,470 Gross margin 2024: € 3,927,470 ▼ 21% vs 2023 (€ 4,959,402) Unfavourable step	€ 3,669,996 Gross margin 2025: € 3,669,996 ▼ 7% vs 2024 (€ 3,927,470) Unfavourable step	▼ 7%
Profit after taxes	€ 533,337 Profit after taxes 2022: € 533,337 First fiscal year in the series	€ 782,618 Profit after taxes 2023: € 782,618 ▲ 47% vs 2022 (€ 533,337) Favourable step	€ 374,589 Profit after taxes 2024: € 374,589 ▼ 52% vs 2023 (€ 782,618) Unfavourable step	€ 594,055 Profit after taxes 2025: € 594,055 ▲ 59% vs 2024 (€ 374,589) Favourable step	▲ 59%
Equity	€ 7,303,779 Equity 2022: € 7,303,779 First fiscal year in the series	€ 8,086,397 Equity 2023: € 8,086,397 ▲ 11% vs 2022 (€ 7,303,779) Favourable step	€ 8,460,986 Equity 2024: € 8,460,986 ▲ 5% vs 2023 (€ 8,086,397) Favourable step	€ 9,055,041 Equity 2025: € 9,055,041 ▲ 7% vs 2024 (€ 8,460,986) Favourable step	▲ 7%
Total debts	€ 2,302,056 Total debts 2022: € 2,302,056 First fiscal year in the series	€ 1,946,676 Total debts 2023: € 1,946,676 ▼ 15% vs 2022 (€ 2,302,056) Favourable step	€ 2,142,365 Total debts 2024: € 2,142,365 ▲ 10% vs 2023 (€ 1,946,676) Unfavourable step	€ 2,177,580 Total debts 2025: € 2,177,580 ▲ 2% vs 2024 (€ 2,142,365) Unfavourable step	▲ 2%
Cash	€ 580,802 Cash 2022: € 580,802 First fiscal year in the series	€ 720,766 Cash 2023: € 720,766 ▲ 24% vs 2022 (€ 580,802) Favourable step	€ 918,132 Cash 2024: € 918,132 ▲ 27% vs 2023 (€ 720,766) Favourable step	€ 467,803 Cash 2025: € 467,803 ▼ 49% vs 2024 (€ 918,132) Unfavourable step	▼ 49%
Retained profit	€ 7,236,779 Retained profit 2022: € 7,236,779 First fiscal year in the series	€ 8,019,397 Retained profit 2023: € 8,019,397 ▲ 11% vs 2022 (€ 7,236,779) Favourable step	€ 8,393,986 Retained profit 2024: € 8,393,986 ▲ 5% vs 2023 (€ 8,019,397) Favourable step	€ 8,988,041 Retained profit 2025: € 8,988,041 ▲ 7% vs 2024 (€ 8,393,986) Favourable step	▲ 7%
Balance sheet total	€ 9,605,835 Balance sheet total 2022: € 9,605,835 First fiscal year in the series	€ 10,033,073 Balance sheet total 2023: € 10,033,073 ▲ 4% vs 2022 (€ 9,605,835) Unchanged	€ 10,603,352 Balance sheet total 2024: € 10,603,352 ▲ 6% vs 2023 (€ 10,033,073) Unchanged	€ 11,232,621 Balance sheet total 2025: € 11,232,621 ▲ 6% vs 2024 (€ 10,603,352) Unchanged	▲ 6%
Employees (FTE)	37.2 Employees (FTE) 2022: 37.2 First fiscal year in the series	34.8 Employees (FTE) 2023: 34.8 ▼ 2.4 vs 2022 (37.2) Unchanged	27.8 Employees (FTE) 2024: 27.8 ▼ 7 vs 2023 (34.8) Unchanged	22.3 Employees (FTE) 2025: 22.3 ▼ 5.5 vs 2024 (27.8) Unchanged	▼ 5.5

Key figures of BIOMEDICAL SYSTEMS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BIOMEDICAL SYSTEMS?

What happened at BIOMEDICAL SYSTEMS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 7, 2026 New annual accounts for financial year 2025: profit of € 594,055 (▲ 59% vs 2024). Source: NBB ↗
2024 Timothy COBB became a director. NBB
2023 Jason KNOBLAUCH became a director. NBB
2022 Christopher FIKRY became a director. NBB
Oct 2, 1981 New establishment in Leuven. KBO
Oct 2, 1981 Start of the company according to the CBE. KBO

In short

From € 533,337 profit in 2022 to € 594,055 profit in 2025.

Paid € 878,976 in corporate taxes since 2022.

Best year ever: 2023, with € 782,618 profit.

On average € 164,600 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Timothy COBB Christopher FIKRY Jason KNOBLAUCH

ArtiQ

BIOMEDICAL SYSTEMS

Behind BIOMEDICAL SYSTEMS are Timothy COBB, Christopher FIKRY and Jason KNOBLAUCH. Timothy COBB is also behind ArtiQ. Jason KNOBLAUCH is also behind ArtiQ.

Directors

According to the 2025 annual accounts

Timothy COBB

Director

Also active at: ArtiQ

since 2024

Christopher FIKRY

Director

since 2022

Jason KNOBLAUCH

Director

Also active at: ArtiQ

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Diestsepoort 1

3000 Leuven

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.

All companies at this address →

LVL7

€ 36,817 gross margin · 2025

ArtiQ same network

€ 1 million gross margin · 2024

VITAMINS@WORK

€ -351,436 gross margin · 2025

HYP3

€ 163,541 gross margin · 2025

EverESSt

€ 170,925 revenue · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0421.984.741

VAT number

BE 0421.984.741

Registered office

Diestsepoort 1, 3000 Leuven

Names & denominations

BIOMEDICAL SYSTEMS

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

2 October 1981

Peppol

Active · Active since 14 May 2026

Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Activiteiten van medische beeldvorming en medische laboratoria

Medische laboratoria

Activiteiten van medische laboratoria

View on CBE Public ↗ Annual accounts (NBB) ↗

BIOMEDICAL SYSTEMS

Warning lights

Financials

What happened to BIOMEDICAL SYSTEMS?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions